IN155158B - - Google Patents

Info

Publication number
IN155158B
IN155158B IN896/DEL/80A IN896DE1980A IN155158B IN 155158 B IN155158 B IN 155158B IN 896DE1980 A IN896DE1980 A IN 896DE1980A IN 155158 B IN155158 B IN 155158B
Authority
IN
India
Application number
IN896/DEL/80A
Other languages
English (en)
Inventor
Peter Gruber
Rolf Brickl
Gerhard Bozler
Herbert Stricker
Original Assignee
Thomae Gmbh Dr K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomae Gmbh Dr K filed Critical Thomae Gmbh Dr K
Publication of IN155158B publication Critical patent/IN155158B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN896/DEL/80A 1980-01-12 1980-12-12 IN155158B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19803000979 DE3000979A1 (de) 1980-01-12 1980-01-12 Neue dipyridamol-retardformen und verfahren zu ihrer herstellung

Publications (1)

Publication Number Publication Date
IN155158B true IN155158B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1985-01-05

Family

ID=6091926

Family Applications (1)

Application Number Title Priority Date Filing Date
IN896/DEL/80A IN155158B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1980-01-12 1980-12-12

Country Status (32)

Country Link
US (1) US4367217A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0032562B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS56103111A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR221983A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE6585T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU539618B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1148084A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CS (1) CS232713B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DD (1) DD156943A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE3000979A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK158539C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES8207428A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI78835C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB2067073B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR73102B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK62184A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU184366B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE50807B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL61887A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN155158B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KE (1) KE3402A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MA (1) MA19040A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY8500559A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO157369C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ195994A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
OA (1) OA06720A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH17063A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL129290B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT72330B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG28184G (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
YU (1) YU42549B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA811661B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
EP0064485B1 (en) * 1981-04-27 1985-07-24 Aktiebolaget Hässle New pharmaceutical preparation
DE3124090A1 (de) * 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
DE3126703A1 (de) 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
IE54171B1 (en) * 1982-06-22 1989-07-05 Univ Glasgow Device for introducing nutrients and/or therapeutic materials into ruminant animals
US4704284A (en) * 1982-08-12 1987-11-03 Pfizer Inc. Long-acting matrix tablet formulations
DE3237575A1 (de) * 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
DK58983D0 (da) * 1983-02-11 1983-02-11 Leo Pharm Prod Ltd Farmaceutisk praeparat
DE3306250A1 (de) * 1983-02-23 1984-08-23 Basf Ag, 6700 Ludwigshafen Sphaerische einkristalle fuer pharmazeutische zwecke
IE55745B1 (en) * 1983-04-06 1991-01-02 Elan Corp Plc Sustained absorption pharmaceutical composition
KR880002139B1 (ko) * 1983-04-08 1988-10-17 베링거 인겔하임 리미티드 경구 투여용 정제의 제조방법
JPS6051106A (ja) * 1983-08-31 1985-03-22 Yamanouchi Pharmaceut Co Ltd 塩酸アモスラロ−ル持続性製剤
IE56459B1 (en) * 1983-12-21 1991-08-14 Elan Corp Ltd Controlled absorption pharmaceutical formulation
GB8414221D0 (en) * 1984-06-04 1984-07-11 Sterwin Ag Unit dosage form
GB8414220D0 (en) * 1984-06-04 1984-07-11 Sterwin Ag Medicaments in unit dose form
US4867984A (en) * 1984-11-06 1989-09-19 Nagin K. Patel Drug in bead form and process for preparing same
DE3627423A1 (de) * 1986-08-13 1988-02-18 Thomae Gmbh Dr K Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
WO1988002629A1 (en) * 1986-10-16 1988-04-21 American Health Products Corporation 2',3'-didesoxyadenosine composition
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US6024983A (en) * 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
IL84599A0 (en) * 1986-12-09 1988-04-29 Byk Gulden Lomberg Chem Fab Pharmaceutical composition containing urapidil and process for the preparation thereof
DE3812799A1 (de) * 1988-04-16 1989-10-26 Sanol Arznei Schwarz Gmbh Oral zu verabreichende pharmazeutische zubereitung mit kontrollierter wirkstofffreisetzung und verfahren zu deren herstellung
GB8813032D0 (en) * 1988-06-02 1988-07-06 Boehringer Ingelheim Int Antiviral pharmaceutical composition
US5196203A (en) * 1989-01-06 1993-03-23 F. H. Faulding & Co. Limited Theophylline dosage form
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5084278A (en) * 1989-06-02 1992-01-28 Nortec Development Associates, Inc. Taste-masked pharmaceutical compositions
AT397345B (de) * 1990-04-04 1994-03-25 Chemiefaser Lenzing Ag Pharmazeutisches präparat mit verzögerter wirkstofffreisetzung auf basis von hemicellulosen
WO1992020326A1 (en) * 1991-05-20 1992-11-26 Marion Laboratories, Inc. Multi-layered controlled release formulation
ES2173096T3 (es) * 1992-08-05 2002-10-16 Faulding F H & Co Ltd Composicion farmaceutica peletizada.
US20060263428A1 (en) * 1993-09-20 2006-11-23 Eugenio Cefali Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6129930A (en) * 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US20060067999A1 (en) * 1996-03-25 2006-03-30 Wyeth Extended release formulation
WO2000018396A1 (fr) * 1998-09-25 2000-04-06 Sankyo Company, Limited PREPARATIONS A BASE D'INHIBITEUR DE HMG-CoA
JP2000159692A (ja) * 1998-09-25 2000-06-13 Sankyo Co Ltd ＨＭＧ―ＣｏＡレダクタ―ゼ阻害薬含有製剤
US6475493B1 (en) 1999-09-02 2002-11-05 Norstrum Pharmaceuticals, Inc. Controlled release pellet formulation
JP2003510349A (ja) * 1999-10-07 2003-03-18 ノヴァ−ニューロン インコーポレーテッド 線条体機能に必要な遺伝子、その使用、およびそれを調節するための化合物
EP1093814A1 (en) * 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders
EP1276470B1 (en) 2000-04-20 2007-05-02 Novartis AG Taste masking coating composition
US7064130B2 (en) * 2001-04-20 2006-06-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
NZ532310A (en) * 2001-10-05 2007-02-23 Combinatorx Inc Combinations comprising a tetra-substituted pyrimidopyrimidine and a corticosteroid for the treatment of immunoinflammatory disorders
DE10149674A1 (de) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
JP2006516593A (ja) * 2003-02-07 2006-07-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｍｍｐ−９依存性疾患の治療及び予防のためのジピリダモール又はモピダモールの使用
DE10306179A1 (de) 2003-02-13 2004-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe
BRPI0409796A (pt) 2003-04-24 2006-05-30 Boehringer Ingelheim Int uso de dipiridamol ou mopidamol para tratamento e prevenção de doenças tromboembolìticas e distúrbios provocados pela formação excessiva de trombina e/ou pela expressão elevada de receptores de trombina
DE10339862A1 (de) * 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
US20050112199A1 (en) * 2003-09-24 2005-05-26 Mahesh Padval Therapeutic regimens for administering drug combinations
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
WO2005113006A2 (en) * 2004-05-13 2005-12-01 Boehringer Ingelheim International Gmbh Use of dipyridamole for treatment of resistance to platelet inhibitors
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
WO2006096434A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2006100281A2 (en) 2005-03-22 2006-09-28 Losan Pharma Gmbh Solubilized ibuprofen
WO2006125042A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of drug-induced sexual dysfunction
CA2617546C (en) 2005-08-03 2014-07-15 Boehringer Ingelheim International Gmbh Use of flibanserin in the treatment of obesity
US20070087056A1 (en) * 2005-08-09 2007-04-19 Claudia Guthmann Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility
US20090214645A1 (en) * 2005-08-22 2009-08-27 Andrea Kramer Pharmaceutical compositions comprising a ph-dependent drug, a ph modifier and a retarding agent
GB0517204D0 (en) * 2005-08-22 2005-09-28 Novartis Ag Organic compounds
CA2626134C (en) * 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
ES2550035T3 (es) * 2006-01-27 2015-11-04 Adare Pharmaceuticals, Inc. Sistemas de administración de fármacos que comprenden un agente de bloqueo selectivo de la serotonina 5-HT3 débilmente básico y ácidos orgánicos
JP5787301B2 (ja) 2006-01-27 2015-09-30 アデア ファーマシューティカルズ，インコーポレイテッド 弱塩基性薬および有機酸を含む薬物送達系
DE602006000819T2 (de) * 2006-02-09 2009-04-09 Teva Pharmaceutical Industries Ltd. Dipyridamol enthaltende Zusammensetzungen mit verlängerter Freisetzung und Verfahren zu deren Herstellung
KR20090005371A (ko) * 2006-05-09 2009-01-13 베링거 인겔하임 인터내셔날 게엠베하 폐경후 성욕 장애의 치료를 위한 플리반세린의 용도
WO2007139753A2 (en) * 2006-05-22 2007-12-06 Combinatorx, Incorporated Methods and compositions for the treatment of diseases or conditions associated with increased c-reactive protein, interleukin-6, or interferon-gamma levels
ATE456369T1 (de) 2006-06-30 2010-02-15 Boehringer Ingelheim Int Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
JP2009543839A (ja) * 2006-07-14 2009-12-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 女性の性的障害を治療するためのフリバンセリンの使用
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
EA200900264A1 (ru) 2006-08-14 2009-08-28 Бёрингер Ингельхайм Интернациональ Гмбх Композиции флибансерина и способ их приготовления
JP5220746B2 (ja) * 2006-08-25 2013-06-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 制御放出システム及びその製造方法
EP1894561A1 (en) * 2006-08-30 2008-03-05 Dr. Reddy's Laboratories Ltd. Dipyridamole pharmaceutical compositions
JP2010522714A (ja) * 2007-03-28 2010-07-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規な医薬組成物
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
US20090075955A1 (en) * 2007-09-19 2009-03-19 Combinatorx, Inc. Therapeutic regimens for the treatment of immunoinflammatory disorders
KR20100121601A (ko) * 2007-12-17 2010-11-18 콤비네이토릭스, 인코포레이티드 면역염증성 질환의 치료를 위한 치료요법
JP5783725B2 (ja) 2007-12-28 2015-09-24 インパックス ラボラトリーズ、 インコーポレイテッドＩｍｐａｘ Ｌａｂｏｒａｔｏｒｉｅｓ， Ｉｎｃ． レボドパの放出制御製剤及びその使用
US20090196935A1 (en) * 2008-02-01 2009-08-06 Ahmed Salah U Pharmaceutical Capsules Comprising Extended Release Dipyridamole Pellets
US8133506B2 (en) 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
WO2010036975A2 (en) * 2008-09-25 2010-04-01 Teva Pharmaceutical Industries Ltd. Dipyridamole and acetylsalicylic acid formulations and process for preparing same
NZ595691A (en) * 2009-04-09 2013-06-28 Alkermes Pharma Ireland Ltd Drug delivery composition
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
EP2361615A1 (en) 2010-02-19 2011-08-31 Alfred E. Tiefenbacher GmbH & Co. KG Dipyridamole prolonged-release tablet
US10098845B2 (en) 2013-10-07 2018-10-16 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
CN105640909B (zh) 2014-11-14 2019-09-20 正大天晴药业集团股份有限公司 一种含有达比加群酯的药用组合物
WO2022140448A1 (en) 2020-12-22 2022-06-30 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2853420A (en) * 1956-01-25 1958-09-23 Lowey Hans Ethyl cellulose coatings for shaped medicinal preparations
US2928770A (en) * 1958-11-28 1960-03-15 Frank M Bardani Sustained action pill
US3081233A (en) * 1960-08-08 1963-03-12 Upjohn Co Enteric-coated pilules
US3247066A (en) * 1962-09-12 1966-04-19 Parke Davis & Co Controlled release dosage form containing water-swellable beadlet
NL297631A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1963-06-03
US3538214A (en) * 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
DE2010416B2 (de) * 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
DE2031871C3 (de) * 1970-06-27 1974-06-27 Roehm Gmbh, 6100 Darmstadt Überzugsmasse für Arzneiformen
GB1468172A (en) * 1973-03-28 1977-03-23 Benzon As Alfred Oral drug preparations
US3954959A (en) * 1973-03-28 1976-05-04 A/S Alfred Benzon Oral drug preparations
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
GB1479655A (en) 1974-03-08 1977-07-13 Beecham Group Ltd Antibiotic preparations
FR2353285A1 (fr) * 1975-09-17 1977-12-30 Doms Laboratoires Medicament vasodilatateur coronarien perfectionne
GB1576376A (en) * 1977-03-30 1980-10-08 Benzon As Alfred Multiple-unit drug dose
LU77353A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1977-05-16 1979-01-19
DD146547A5 (de) 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
IE48715B1 (en) * 1978-12-22 1985-05-01 Elan Corp Plc New galencial forms for administration of medicaments by oral route,with programmed release and processes for preparing same

Also Published As

Publication number Publication date
ES498393A0 (es) 1982-09-16
MY8500559A (en) 1985-12-31
MA19040A1 (fr) 1981-10-01
DK9481A (da) 1981-07-13
GB2067073A (en) 1981-07-22
ES8207428A1 (es) 1982-09-16
FI78835B (fi) 1989-06-30
DD156943A5 (de) 1982-10-06
CS23281A2 (en) 1984-06-18
FI78835C (fi) 1989-10-10
PT72330A (de) 1981-02-01
ZA811661B (en) 1982-09-29
FI810058L (fi) 1981-07-13
ATE6585T1 (de) 1984-03-15
GB2067073B (en) 1984-02-15
AU539618B2 (en) 1984-10-11
YU3981A (en) 1983-09-30
EP0032562B1 (de) 1984-03-14
SG28184G (en) 1985-02-15
CS232713B2 (en) 1985-02-14
IE50807B1 (en) 1986-07-23
NO157369B (no) 1987-11-30
IE810040L (en) 1981-07-12
AU6615681A (en) 1981-07-16
DE3067058D1 (en) 1984-04-19
JPS56103111A (en) 1981-08-18
PH17063A (en) 1984-05-24
YU42549B (en) 1988-10-31
JPS6116368B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1986-04-30
KE3402A (en) 1984-06-08
NO810061L (no) 1981-07-13
CA1148084A (en) 1983-06-14
NO157369C (no) 1988-03-16
NZ195994A (en) 1984-04-27
PL129290B1 (en) 1984-04-30
DE3000979A1 (de) 1981-07-23
HU184366B (en) 1984-08-28
PL229157A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1981-09-18
DK158539B (da) 1990-06-05
HK62184A (en) 1984-08-17
GR73102B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1984-02-02
EP0032562A1 (de) 1981-07-29
AR221983A1 (es) 1981-03-31
US4367217A (en) 1983-01-04
PT72330B (de) 1982-07-23
DK158539C (da) 1990-11-05
IL61887A (en) 1984-09-30
OA06720A (fr) 1982-06-30

Similar Documents

Publication Publication Date Title
FR2474105B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE3153253A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR73102B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2493112B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR75330B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2480927B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2474075B3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2474064B3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2474592B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE3152276T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2474358B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2491222B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2474440B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2474357B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH655674B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2474623B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2474341B3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2474060B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2490532B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2474174B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2474365B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2474028B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2474281B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2474119B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2474566B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)